TYRA - NASDAQ

Tyra Biosciences, Inc.

Tyra Biosciences, Inc.

TYRAยทNASDAQ

$28.69

-5.6%
HealthcareBiotechnology

Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$1.71B
EPS-2.0100
P/E Ratio-14.27
Earnings Date08/06/2026
Tyra Biosciences, Inc.

Tyra Biosciences, Inc. Fair Value Envelope

TYRA ยท NASDAQ

Our analysis suggests that TYRA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $28.69, this represents a potential HIDDEN relative to our calculated worth for Tyra Biosciences, Inc..

HIDDEN
Intrinsic Value
Current Price: $28.69

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$141.5M
+ Cash & Equivalents$77.4M
Firm Value-$64.1M
- Debt$5.8M
Equity Value-$69.9M
/ Shares Outstanding53,318,198B
DCF Value-$1
OVERVALUED BY 105%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$61.6M
-$39.9M
-$25.8M
-$16.7M
-$10.8M
-$7.0M
-$4.5M
-$2.9M
-$1.9M
-$1.2M
Maintenance CapEx
-$18.3K
-$11.8K
-$7.6K
-$5.0K
-$3.2K
-$2.1K
-$1.3K
-$869
-$562
-$364
Owner Earnings
-$61.6M
-$39.9M
-$25.8M
-$16.7M
-$10.8M
-$7.0M
-$4.5M
-$2.9M
-$1.9M
-$1.2M
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$57.0M
-$34.2M
-$20.5M
-$12.3M
-$7.4M
-$4.4M
-$2.6M
-$1.6M
-$949.5K
-$569.1K
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your TYRA research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.